These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20347440)

  • 1. [Dopaminergic malignant syndrome due to acute withdrawal of l-dopa].
    Romero FJ; Santisteban-López Y; Moreno-Salcedo JM; Ramírez-Relinque L
    Rev Clin Esp; 2010 May; 210(5):254-5. PubMed ID: 20347440
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome.
    Nisijima K; Noguti M; Ishiguro T
    Biol Psychiatry; 1997 Apr; 41(8):913-4. PubMed ID: 9099421
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Malignant dopaminergic syndrome].
    Adarraga Cansino MD; Zambrana García JL; Velasco Malagón MJ; Rosa Jiménez F
    Med Clin (Barc); 2004 Apr; 122(12):477. PubMed ID: 15104962
    [No Abstract]   [Full Text] [Related]  

  • 6. [A case of impending neuroleptic malignant syndrome associated with Shy-Drager syndrome].
    Kumagai R; Harada T; Kurokawa K; Okazaki M; Egi N; Shimote K; Nakamura S
    No To Shinkei; 1998 Aug; 50(8):745-9. PubMed ID: 9757468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of lisuride in the treatment of neuroleptic malignant syndrome.
    de Mari M; Lamberti P; Simone F; Iliceto G; Federico F; Ferrari E
    Funct Neurol; 1991; 6(3):285-8. PubMed ID: 1683852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuroleptic malignant syndrome--a review.
    Gibb WR; Lees AJ
    Q J Med; 1985 Aug; 56(220):421-9. PubMed ID: 2864716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of liposomal form of L-Dopa on the development of parkinsonian syndrome in mice].
    Kucherianu VG; Iurasov VV; Kryzhanovskiĭ GN; Nikushkin EV; Zhigal'tsev IV; Kaplun VP; Shvets VI
    Biull Eksp Biol Med; 1997 Jan; 123(1):29-33. PubMed ID: 9213451
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome without withdrawal of levodopa.
    Singla R; Singla A; Kumar S; Kar P
    Natl Med J India; 2009; 22(3):162. PubMed ID: 19764697
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV; Podgornyĭ GI; Kucherianu VG; Kudrin VS; Nikushkin EV; Zhigal'tsev IV; Sandalov IuG; Kaplun AP; Shvets VI; Kryzhanovskiĭ GN
    Biull Eksp Biol Med; 1996 Dec; 122(12):614-7. PubMed ID: 9280455
    [No Abstract]   [Full Text] [Related]  

  • 13. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
    Onofrj M; Bonanni L; Cossu G; Manca D; Stocchi F; Thomas A
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S233-6. PubMed ID: 20082998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome complicating levodopa withdrawal.
    Reutens DC; Harrison WB; Goldswain PR
    Med J Aust; 1991 Jul; 155(1):53-4. PubMed ID: 2067442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malignant-like neuroleptic syndrome: a sign to call attention to].
    Segado Soriano A; García Castaño J; del Toro Cervera J; Muiño Miguez A
    An Med Interna; 1995 Sep; 12(9):466-7. PubMed ID: 8924562
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
    Rainer C; Scheinost NA; Lefeber EJ
    Postgrad Med; 1991 Apr; 89(5):175-8, 180. PubMed ID: 2008397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroleptic malignant syndrome: a review of literature].
    Crespo Facorro B; Carbonell Masia C
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1995; 23(5):273-8. PubMed ID: 8553925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?
    Avanzi M; Baratti M; Cabrini S; Uber E; Brighetti G; Bonfà F
    Parkinsonism Relat Disord; 2008; 14(3):257-8. PubMed ID: 17561433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine dysregulation syndrome in a patient with restless legs syndrome.
    Leu-Semenescu S; Karroum E; Brion A; Konofal E; Arnulf I
    Sleep Med; 2009 Apr; 10(4):494-6. PubMed ID: 19410183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance.
    Ladha SS; Walker R; Shill HA
    Mov Disord; 2005 May; 20(5):630-1. PubMed ID: 15719433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.